Considerations for Practice

Limiting dietary iron intake can slow tumour growth and increase the efficacy of some cancer therapies, according to a new animal study. Researchers used mouse models to demonstrate that iron depletion can weaken tumours by increasing their dependency on angiogenesis, making them less able to resist antiangiogenic therapies. Iron reduction may therefore provide a simple and effective way of enhancing current therapies in patients with cancer. However, the lack of data regarding the survival of the mice means it is difficult to apply these findings to humans.

Professor Michael Bohm at ESC 2012
Professor John Cleland at ESC 2012
Professor Alain Cohen-Solal at ESC 2012
Professor Dirk van Veldhuisen at ESC 2012

In 2012, the European Society of Cardiology (ESC) published updates to their Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. For the first time, the guidelines consider iron deficiency as a significant co-morbidity in its own right, independently of anaemia, reflecting the growing awareness of the condition as a significant barrier in the management of heart failure.

Adolescent females with heavy menstrual bleeding (HMB) experience greater fatigue than their healthy counterparts, new data indicates. This does not appear to be linked to differences in iron status, though major limitations of the study design, including low participant numbers and significant confounding factors, make interpretation of these results difficult.

The European Renal Best Practice (ERBP) group has published a statement in response to some of the recommendations laid out in the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for anaemia management in chronic kidney disease1. The group felt that some of the KDIGO recommendations were ‘soft’ and that the global guidelines needed to be adapted for implementation at a European level.


Subscribe to RSS - Considerations for Practice